Get the latest news, insights, and market updates on TLSI (TriSalus Life Sciences, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo., October 30, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be iss Oct 30, 2025 - $TLSI
TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
WESTMINSTER, Colo., August 28, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the follo Aug 28, 2025 - $TLSI
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
DENVER, August 12, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. Aug 12, 2025 - $TLSI
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
WESTMINSTER, Colo., August 11, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympto Aug 11, 2025 - $TLSI
TriSalus Life Sciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
WESTMINSTER, Colo., July 30, 2025--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025 at 9:00 a.m. ET. Management will also host investor meetings during Jul 30, 2025 - $TLSI
TriSalus Life Sciences to Host Second Quarter 2025 Financial Results Conference Call
WESTMINSTER, Colo., July 29, 2025--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) ("TriSalus" or the "Company"), a company working to improve outcomes for patients with solid tumors by combining innovative drug delivery, current on-market therapeutics and immunotherapy, announced today that it will host a conference call and webcast on Tuesday August 12, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2025. A press release detailing the results will be i Jul 29, 2025 - $TLSI
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" lets us enhance your experience and provide personalized content and ads.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple